How do I buy AstraZeneca (AZN) stock?

Buying AstraZeneca (AZN) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "AZN", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy AZN by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if AZN is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

AstraZeneca (AZN) Stock

Q: What is the minimum investment for AZN on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in AstraZeneca from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NYSE · AZN

Trade AZN

Key stats

Market cap: $293.14B
Price / Earnings ratio: 25.9x
EPS (TTM): $7.12
Volume: Loading
52-week high: $212.71
52-week low: $80.48
Dividend yield: 1.70%
Dividend amount (latest): $1.06
EPS vs analyst estimate: +4.4%Q3 FY25 · $1.19 vs $1.14

Source: third-party data provider, as of November 5, 2026

EPS estimate: analyst consensus

Compare with AZN

Technical indicators

RSI 14: 73.52
MACD 12/26/9: 5.92
EMA 9 of MACD: 3.68
MACD histogram: 2.24
SMA 50: $165.62; Price above SMA 50
EMA 50: $168.82; Price above EMA 50
SMA 200: $180.17; Price above SMA 200
EMA 200: $177.13; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 4, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 1 analyst rating

Strong Sell0

Sell0

Hold0

Buy1

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2025

70B47B23B0

Debt & Balance Sheet

Total assets

Total liabilities

2025

137B90B45B0

Revenue to Profit

2025

$58.7B

Revenue

$0.0

Cost of revenue

$48.1B

Gross profit

$0.0

Operating expenses

$10.2B

Net income

Earnings

EPS forecast

Actual EPS

$1.19

$1.14

Q3FY25

$1.09

Q4FY25

$1.24

Q1FY26

$1.25

Q2FY26

$1.34

Q3FY26

The market is expecting earnings per share of $1.34 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide

SectorHealthcare

IndustryDrug Manufacturers - General

Employees96,100

CEOMr. Pascal Claude Roland Soriot D.V.M., M.B.A.

IPO DateMay 17, 1993

HeadquartersCambridge, United Kingdom

Key Executives

Name	Title	Year Born
Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.	CEO & Executive Director	1959
Dr. Aradhana Sarin M.D.	CFO & Executive Director	1974
Ms. Pam P. Cheng	EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board	1970
Mr. Joris Silon	Head of Investor Relations	—
Mr. Jeffrey Pott J.D.	CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board	—
Dr. Ruud Dobber Ph.D.	Executive Vice-President of BioPharmaceuticals Business Unit	—
Dr. Susan Mary Galbraith M.D., Ph.D.	Executive Vice President of Oncology R&D	1966
Ms. Iskra Reic	Executive Vice President of International	—
Mr. David Fredrickson	Executive Vice-President of Oncology Haematology Business Unit	1975
Ms. Ruth March FMEDSCI, O.B.E., Ph.D.	Senior VP of Precision Medicine - R&D Oncology	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-13.0	+6.1
2022	-0.2	+5.5	+8.2	-0.6	+0.1	-0.1	+0.4	-5.0	-11.2	+5.9	+13.6	-0.8
2023	-5.7	+2.5	+6.4	+4.7	-0.6	-1.7	+9.9	-5.1	-0.6	-5.2	+1.3	+4.0
2024	-2.6	-4.0	+4.9	+12.8	+2.1	-1.3	+1.6	+7.9	-9.1	-9.6	-5.3	-2.3
2025	+7.4	+9.1	-3.4	-1.1	+3.3	-2.8	+2.3	+8.0	-4.3	-2.3	+13.5	+1.6
2026	+1.3	+10.6	-3.2	-6.7	+0.5	+5.5	-7.7	+2.6	-0.6	+18.4	-1.4

Stocks in the same sector

FAQ

Buying AstraZeneca (AZN) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "AZN", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy AZN by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in AstraZeneca from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Yes, AstraZeneca regularly pays dividends to shareholders. Currently, the estimated dividend yield for AZN is around 1.70% per year. On Gotrade, cash dividends will be automatically credited to your account balance (after taxes).

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

AstraZeneca (AZN) Stock

Key stats

Compare with AZN

Recent news

RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report

RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report

SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus

SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus

AstraZeneca: 3 Key Takeaways for Long-Term Investors

AstraZeneca: 3 Key Takeaways for Long-Term Investors

AstraZeneca Q3 Earnings Call Highlights

AstraZeneca Q3 Earnings Call Highlights

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report

RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report

SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus

SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus

AstraZeneca: 3 Key Takeaways for Long-Term Investors

AstraZeneca: 3 Key Takeaways for Long-Term Investors

AstraZeneca Q3 Earnings Call Highlights

AstraZeneca Q3 Earnings Call Highlights

AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth

AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth

AstraZeneca Gaps Up To Three-Month High As CEO Calls Out $20 Billion Potential

AstraZeneca Gaps Up To Three-Month High As CEO Calls Out $20 Billion Potential

Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

AstraZeneca CFO on AI, Earnings, Restructuring Plan

AstraZeneca CFO on AI, Earnings, Restructuring Plan

AstraZeneca CEO Sees Over $20B Potential From 2027 Drug Trial Readouts – AZN Stock Eyes Breakout After Q3 Earnings Beat

AstraZeneca CEO Sees Over $20B Potential From 2027 Drug Trial Readouts – AZN Stock Eyes Breakout After Q3 Earnings Beat

FTSE 100 set for monthly gains; AstraZeneca up after results

FTSE 100 set for monthly gains; AstraZeneca up after results

About AstraZeneca

Key Executives

Fundamentals

Valuation

Profitability

Trading

Dividend

Technical indicators

Analyst views

Seasonality

Corporate actions

Upcoming

Past

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade